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We found the prevalence of recurrent lymphocytic men-
ingitis associated with herpes simplex virus type 2 (HSV-2) 
was 2.2/100,000 population in Finland during 1996–2006, 
higher than previous estimates. PCR was most sensitive in 
detecting HSV-2 DNA from cerebrospinal fluid if the sample 
was taken 2–5 days after symptom onset. 
R
ecurrent lymphocytic meningitis (RLM) is a rare dis-
ease, characterized by attacks of sudden onset asep-
tic meningitis followed by complete recovery and unpre-
dictable recurrences. The disease is most often caused by 
herpes simplex virus type 2 (HSV-2) and less frequently 
by  other  viruses,  autoimmune  disorders,  or  medication. 
Symptomatic episodes of RLM usually subside within 5 
years, but the total number of episodes may reach 30. Pa-
tients are typically middle-aged, and women are more often 
affected than men (1–3). In addition to symptoms typical 
of meningitis, ≈50% of patients have transient hallucina-
tions, seizures, cranial nerve palsies, or an altered level of 
consciousness (4).
The Study
This study was conducted at Helsinki University Cen-
tral Hospital, Finland, which serves a population of 1.4 mil-
lion. The prevalence study covered January 1996 through 
December 2006. This period differed from that of the pa-
tient study because the World Health Organization’s coding 
system changed in 1996 to the International Classification 
of Diseases, 10th Revision. Diagnostic codes A87, B00.3 
+ G02.0, B01.0 + G02.0, B02.1, G02*, G03.0, G03.1 and 
G03.2 were used to identify study cases.
The patient study was conducted from January 1994 
through December 2003. All patients with RLM (>2 clini-
cal episodes, lymphocytic predominance and negative bac-
terial culture from cerebrospinal fluid [CSF], and HSV-2 
DNA in at least 1 CSF sample) were recruited. A struc-
tured questionnaire was used to interview patients about 
symptoms during and after meningitis episodes. Antibodies 
against HSV types 1 and 2 were tested on the study entry 
day, which was at least 1 month after the most recent RLM 
episode. Sixty-two age- and sex-matched healthy partici-
pants served as controls in the laboratory analysis.
Type-specific HSV-1 and -2 immunoglobulin (Ig) G 
and IgM were measured by enzyme immunoassay (Herpe-
Select 1&2 ELISA IgG; Focus Diagnostics, Cypress, CA, 
USA; and EIAgen HSV IgM; Adaltis, Bologna, Italy). The 
detection of HSV DNA in CSF samples was performed as 
described (5).
Statistical  comparisons  between  groups  were  made 
by using a permutation test for titiers of antibodies against 
HSV-2, and Fisher exact test for HSV seropositivity. Ka-
plan-Meier estimate was used to illustrate information on the 
cumulative proportions of the second meningitis episode.
During  the  prevalence  study,  from  January  1996 
through December 2006, a total of 665 patients were treat-
ed at the Helsinki University Central Hospital for lympho-
cytic meningitis. Meningitis was recurrent in 37 patients 
(5.6%). Twenty-eight patients with RLM had HSV-2 DNA 
in CSF. In addition, 3 patients had recurring genital her-
pes and elevated HSV-2 serum titers. Thus, the minimum 
11-year period prevalence of RLM was 2.7/100,000 popu-
lation (95% confidence interval [CI] 1.9–3.7) and that of 
HSV-2  associated  RLM  2.2/100,000  population.  HSV-2 
was the likely etiologic agent in 84% of all RLM cases. Six 
patients (16%) had no herpetic etiology. One had systemic 
lupus and 1 had Sjögren syndrome; in 4 patients, etiology 
remained unknown.
During the patient study, from January 1994 through 
December 2003, 86 patients had a CSF sample positive for 
HSV DNA. Of these patients, 23 (27%) were diagnosed 
with RLM; 22 case-patients (age: mean 40 years, range 25–
55 years; 18 females, 4 males) were enrolled in the study.
HSV-1 seropositivity was less common in case-patients 
than in controls (25% vs. 52%; p = 0.043). All case-patients 
and 19% of the controls were seropositive for HSV-2 (p = 
0.003). IgG antibody titers against HSV-2 were higher in 
case-patients than in seropositive controls (median 118 vs. 
79; p = 0.034). IgM against HSV was not detected in 96% 
of the episodes.
The  22  case-patients  had  a  combined  95  episodes 
(mean  4.3)  of  meningitis.  The  presence  of  HSV  DNA 
in CSF had been analyzed during 48 episodes (Table 1). 
HSV-2 DNA was present in 82% of the samples taken 
during the first 2–5 days, and in 46% of samples obtained 
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tained either earlier or later, no HSV-2 DNA was detected, 
despite previous HSV-2 DNA-positive episodes. The me-
dian leukocyte count during the first HSV-2 PCR positive 
episode was 350 cells/mm3 (range 44–1,410 cells/mm3). In 
PCR negative cases, the leukocyte counts were lower.
The  median  patient  follow-up  time  was  16.2  years 
(range 4–32 years). The number of meningitis episodes per 
case-patient varied from 2 to 13 (Table 1), and the number 
of meningitis episodes per follow-up year was 0.28 (95% 
CI 0.22–0.35). The time between the first and the second 
episode of meningitis ranged from 1 to 216 months (me-
dian 47 months; Figure).
Eight  case-patients  (36%)  reported  paresthesias  and 
7 (32%) had neuropathic pain during or after meningitis 
(Table 2). The pain typically radiated to the extremities, 
followed a dermatome pattern, and could last up to several 
years after meningitis. Arthralgias (n = 6) and urinary dys-
function (n = 5) were common.
In 56 (61%) of the 95 episodes, case-patients received 
antiviral medication to alleviate symptoms. Seven case-
patients (32%) used daily antiviral medication to prevent 
new episodes; 2 experienced new episodes despite the 
medication.
Five case-patients (23%) experienced their first episode 
of meningitis after symptomatic HSV-2 genital herpes; 4 of 
these case-patients were HSV-1 seronegative at that time. 
In 4 case-patients (18%), genital herpes recurred frequently 
(more than 6 episodes per year). Four case-patients (18%) 
had a history of labial herpes; 7 (32%) had no history of 
herpetic infections.
Conclusions
The prevalence of HSV-2–associated RLM has been 
estimated to be 1/100,000 population (6). According to our 
study, the 11-year prevalence of HSV-2–associated RLM 
was higher, 2.2/100,000 population. Because the disease 
is only periodically active with long asymptomatic peri-
ods, its accurate prevalence in the population is difficult to   
define.
Paresthesias, neuropathic pain, arthralgias, and urinary 
dysfunction  were  common  during  and  after  meningitis. 
Case reports have described paresthesias associated with 
meningitis (7,8). Radiculomyelitis, urinary retention, and 
neuralgia associated with HSV-2 genital herpes have been 
reported, but rarely in connection with RLM (9–11).
The case-patients in our study were less often sero-
positive  for  HSV-1,  and  their  IgG  titers  against  HSV-2 
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Table 1. Presence of HSV type 2 DNA in CSF, leukocyte count, and timing of CSF samples in 22 patients with recurrent lymphocytic
meningitis, through December 2007, Finland* 
Patient
no. Age, y 
No.
episodes
Period
(first episode–latest episode)  HSV-2 DNA in CSF 
Leukocyte counts and timing of 
CSF samples in PCR-tested cases
1 29 7 2000–2004 NT, P, NP, NT, NP, NP, NP  44,† 18,‡ 4,‡ 2,‡ 1§ 
2 55 9 1985–2004 NT, NT, NT, NT, NT, P, P, NP, NP  219,§ 221,§ 9,† 3† 
3 44 4 1990–1998 NT, NT, NT, P  310§
4 43 4 1988–2000 NT, NT, NT, P  790§
5 33 4 1994–1998 NT, P, P, P  1,410,§ ¶,§ 73§
6 32 4 1996–2002 P, NP, NP, NP  164,§ 64,† 32,† 93† 
7 48 5 1979–2002 NT, NT, NT, P, NT  196§
8 33 4 1998–2005 NT, P, NP, NP  360,† 238,§ 239# 
9 36 13 1990–2007 NT, NT, NT, NT, NT, NT, NT, NT, 
P, NP, NP, NP, NP 
195,§ 2,† 0,† 260,§ 1‡ 
10 40 4 1990–1994 NT, NT, P, NT  40¶
11 47 2 2001–2003 P, NP  1,006,§ 790§ 
12 40 2 1989–1997 NT, P  325§
13 36 2 2001–2004 P, P  592,§ 620§
14 38 2 1991–1996 NT, P  92§
15 51 3 1975–1998 NT, NT, P  680†
16 38 7 1992–2006 NT, P, NT, NP, NT, NT, P  160,† 16,‡ 106§
17 51 3 1984–1998 NT, NT, P  360†
18 39 3 1989–2004 NT, NT, P  172§
19 45 5 1980–2004 NT, NT, NT, P,P   350,§ 203§
20 25 2 2002–2004 P, NP  1,350,§ 430§
21 33 4 1995–2007 P,P, P, NT  720,§ 306,§ ¶§ 
22 38 2 1990–1999 NT, P  645†
*HSV, herpes simplex virus; CSF, cerebrospinal fluid; NT, HSV DNA not tested; P, HSV-2 DNA present in CSF; NP, HSV-2 DNA not present in CSF. 
Boldface indicates HSV-2 DNA present in the sample.  
†CNF sample taken 24–48 h after first symptoms. 
‡CSF sample taken within 24 h of the first symptoms.  
§CSF sample taken 2–5 days after first symptoms.  
¶Leukocyte count or timing of the sample not known. 
#CSF sample taken >5 days after first symptoms. Recurrent Lymphocytic Meningitis
were higher than in controls. Lately, the seroprevalence of 
HSV-1 has declined in developed countries, while that of 
HSV-2 has increased. Complications after the disease may 
be more frequent in HSV-2 infections without preceding 
HSV-1 infection (12).
In an earlier study, during a 1-year follow-up, recurrent 
disease developed in 18% of patients with HSV-2 DNA in 
CSF (11). In our study, during the 10-year follow-up, the 
percentage of case-patients with recurrent disease was 27% 
of all HSV-2 DNA-positive cases.
In RLM, all episodes are most likely caused by the 
same  etiologic  agent.  However,  HSV-2  DNA  is  not  al-
ways found in CSF, despite earlier HSV-2 DNA–positive 
episodes. The viral load and leukocyte counts reach higher 
levels during the first episode of meningitis compared with 
recurrent cases (13). False-negative results may be due to 
a lower viral load or to earlier timing of the CSF sample in 
recurrent episodes (14). In our study, most PCR-positive 
samples were taken 2–5 days after the onset of acute symp-
toms, which is considered to be optimal timing. Clinical 
symptoms were alleviated in recurrent episodes, probably 
because of milder inflammatory changes in the CNS and 
lower viral load, which may result in PCR becoming less 
sensitive in diagnosis.  
HSV-2–associated RLM is more common than pre-
viously reported. Prophylactic antiviral therapy may have 
decreased the incidence of recurrences but was not uni-
versally effective. In case-patients with frequent relapses, 
the recovery was prolonged, and residual symptoms were 
common.  
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Table 2. Clinical symptoms in 22 patients with recurring herpes simplex virus (HSV) type 2 meningitis, during study period (January 
1994–December 2003), Finland 
No. patients with symptom 
Associated symptoms  During meningitis episode  After meningitis episode  Total* Maximum duration 
Neuropathic pain  5 6 7 Years 
Paresthesias 8 6 8 Months
Urinating difficulty  3 3 5 Months
Arthralgias 1 6 6 Months
Paresis of facial nerve  1 1 2 Weeks
Hallucinations 1 0 1 Days 
Dysarthria  3 0 3 Days 
Visual disturbance  2 0 2 Days 
*Some patients experienced symptoms both during and after episodes. 
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